Sanofi SA vs Seagate Technology Holdings PLC — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Seagate Technology Holdings PLC trades at $905 (market cap $181.56B). The key difference: Seagate Technology Holdings PLC is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | STX | |
|---|---|---|
Market Cap | $104.83B | $181.56B |
Sector | Health | Technology |
52-Week High | $52.34 | $1.09K |
52-Week Low | $41.33 | $146.59 |
Enterprise Value | $121.32B | $184.59B |
Dividend Yield | 5.5% | 0.37% |
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Seagate Technology (STX) trades at $891.23, up 13.25% over the past 24 hours, with strong recent earnings beats and bullish analyst sentiment. The stock shows bearish technical signals but benefits from robust profitability metrics including a 21.6% net income margin and 96.27% ROE. Recent news highlights AI-driven storage demand as a key growth catalyst, with the company set to report Q2 2026 earnings on July 28, 2026.
Outlook remains positive due to AI infrastructure expansion and consistent earnings outperformance, though high valuation ratios and negative shareholder equity pose risks. Analyst consensus price target of $987.86 suggests upside potential, but investors should monitor debt levels and competitive pressures in the storage sector.
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →